Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from JJ.

A CEO contender left Johnson & Johnson. Was she penalized for saying she wanted the job?

The exit of a Johnson & Johnson exec raises an age-old question about women's ambition.

Fortune

Johnson & Johnson says it's finally making 'progress' on disturbing cancer lawsuits

J&J is facing tens of thousands of cases involving its talc-based powder.

The Street

His dad worked on the factory floor at Johnson & Johnson. Now he’s the CFO

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs

In a series of moves experts say signal a shift in how developing countries deal with pharmaceuticals, South Africa, Colombia and others have recently adopted a more combative approach towards drugmakers, pushing back on policies that deny treatment to millions of people with tuberculosis and HIV

The Independent UK

2 Dividend Kings Warren Buffett Just Dumped

The legendary value investor slashed two consistent dividend-paying stocks from Berkshire Hathaway's portfolio in the latest quarter, according to regulatory filings.

Barchart

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Fortune

Johnson & Johnson not to enforce patents on TB drug

“The announcement will finally pave the way for unfettered access to affordable generic versions of bedaquiline for all people”

The Hindu

Read news from The Economist, FT, and more,
with one subscription

This J&J exec sold Tylenol and Listerine. Now she runs its $27B medtech business

Ashley McEvoy pivoted from over-the-counter products to medical devices.

Fortune

Big Pharma's Johnson & Johnson under investigation in South Africa over 'excessive' drug prices

U.S.-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for allegedly charging “excessive” prices for a key tuberculosis drug

The Independent UK

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

The Independent UK

South Africa ‘held to ransom’ by big pharma, overcharged for COVID vaccines

J&J, Pfizer charged South Africa between 15 and 33 percent more for COVID vaccine doses, contracts reveal.

Al Jazeera

Cost of tuberculosis treatment halved in deal to permit generic versions

Johnson & Johnson’s year-long deal on life-saving drug bedaquiline is seen as critical move in campaign against disease

The Guardian - UK

Kenvue Joins S&P 500 on Friday: Time to Buy?

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Barchart

Jim Cramer Has a Weird Problem With Johnson & Johnson

"Hope," he said, "should never be a part of the investing equation."

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

The Hindu

Explained | Will generic supply of bedaquiline be accessible?

J&J's patent on bedaquiline expired, allowing generic manufacturers to supply the drug. J&J has filed secondary patents. Prices are expected to reduce 3-6x, but some countries are excluded from the deal, raising concerns.

Investors Business Daily

J&J Stock Roars Higher, Retaking Its 200-Day Line As Small Drugs Drive Big Beat

Johnson & Johnson beat quarterly expectations Thursday, helped by its new cancer drug Carvykti, and JNJ stock surged.

The Hindu

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India

MSF reiterated its call for Johnson & Johnson to publicly announce that it will not enforce any ‘secondary’ patents for bedaquiline in any country with a high burden of TB, as J&J’s 20-year primary patent on bedaquiline expired on July 18.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Cheaper TB drugs for millions after global deal on patent rights agreed

Johnson & Johnson allows generic bedaquiline in 44 countries – but concerns remain about ‘stopgap’ solution

The Independent UK

Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign

Disease kills millions each year even though it’s curable

Fortune

Future Fortune 500 CEOs: 11 up-and-comers that leadership experts see as generational standout bosses

Fortune has identified 11 CEO stars in the making—many of them already in the C-suite, and all potential large-company CEOs.

Edinburgh Live

Edinburgh to get huge Harry Styles Aftershow Parties with 'Harryoke' and star's hits

The Love On Tour Aftershow Party is coming to Edinburgh, with the event hosted by the Harry’s House Party, the creators of the original Harry Styles and One Direction club night.

Guitar World

PRS Sonzera 20 Combo review

Reworked, redesigned, reinvigorated, PRS's versatile combo returns – and it's a bona-fide 20-watt powerhouse of tone

Tribune News Service

J&J wins pause of baby powder trials, must face new suits

Johnson & Johnson must face new lawsuits accusing the company of selling tainted baby powder that caused cancer, a judge ruled, opening the company up to court actions that had been halted for 19 months.

Investors Business Daily

Legend Breaks Out After Leaked Documents Show Promise In $9.6 Billion Market

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.